MRNA
NASDAQModerna Inc.
Price$153.99-3.30 (-2.10%)
01:30 PM07:45 PM
News · 26 weeks93-7%
2026-03-292026-09-20
Mix4490d
- Insider17(39%)
- Market11(25%)
- Other6(14%)
- SEC Filings5(11%)
- Analyst5(11%)
Latest news
25 items- INSIDERPresident Hoge Stephen exercised 152,905 shares at a strike of $12.21 and sold $11,691,420 worth of shares (80,575 units at $145.10) as part of a pre-agreed trading plan, increasing direct ownership by 5% to 1,562,029 units (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- PRA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The global antiviral drugs market was valued at roughly $42.3 billion in 2025 and is projected to reach approximately $57.8 billion by 2034. But those numbers only tell part of the story. The bigger opportunity may be
- INSIDERChief Financial Officer Mock James M exercised 19,836 shares at a strike of $30.96 and sold $4,685,094 worth of shares (34,836 units at $134.49) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 59,375 units (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 9% to 74,375 units (SEC Form 4) (for tax liability)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 8% to 81,340 units (SEC Form 4) (withholding obligation)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Legal Officer Klinger Shannon Thyme sold $485,766 worth of shares (3,471 units at $139.95) as part of a pre-agreed trading plan, covered exercise/tax liability with 1,048 shares and exercised 5,637 shares at a strike of $19.06, increasing direct ownership by 2% to 75,247 units (SEC Form 4) to cover withholding tax4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Financial Officer Mock James M covered exercise/tax liability with 1,197 shares and converted options into 2,475 shares, increasing direct ownership by 2% to 68,282 units (SEC Form 4) (for withholding tax)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERPresident Hoge Stephen converted options into 9,283 shares and covered exercise/tax liability with 4,489 shares, increasing direct ownership by 0.32% to 1,489,699 units (SEC Form 4) (tax liability)4 - Moderna, Inc. (0001682852) (Issuer)
- ANALYSTModerna downgraded by Rothschild & Co Redburn with a new price targetRothschild & Co Redburn downgraded Moderna from Neutral to Sell and set a new price target of $81.00
- SECModerna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Moderna, Inc. (0001682852) (Filer)
- NEWSModerna to Present at Upcoming Conferences in September 2026CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ETBernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.m. ETA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaModerna is a pione
- INSIDERPresident Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Financial Officer Mock James M converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.85% to 67,004 units (SEC Form 4) to satisfy withholding obligation4 - Moderna, Inc. (0001682852) (Issuer)
- ANALYSTModerna upgraded by Argus with a new price targetArgus upgraded Moderna from Hold to Buy and set a new price target of $180.00
- NEWSModerna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior NotesProceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debtModerna has also purchased a hedge overlay intended to offset dilution up to a cap initially equal to a 175.0% premium to the stock price at pricing CAMBRIDGE, MA / ACCESS Newswire / August 28, 2026 / Moderna, Inc. (NASDAQ:MRNA) ("Moderna"), today announced the pricing of $2.6 billion aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933,
- NEWSModerna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 VaccinesCAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19.The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition placing them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. mNEXSPIKE, Moderna's latest COVID-19 vaccine, is approved
- NEWSModerna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior NotesProceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debtModerna will also purchase a hedge overlay intended to offset dilution up to a cap initially equal to at least a 150% premium to the stock price at pricing CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) ("Moderna"), today announced that it intends to offer, subject to market conditions and other factors, $2.0 billion aggregate principal amount of Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") only to persons reasonably believed to be "qualified institutional buye
- PRA Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is surprisingly straightforward: instead of giving the immune system a one-size-fits-all treatment, an mRNA vaccine can be designed to teach it what a particular tumor looks like and help it go after those cancer cells. That matters in lung cancer because every tumor can be different, and some eventually learn how to get around existing treatments. Researchers are now looking at whether personalized mRNA vaccines can work alongside today’s immunotherapies to give the immune system a
- ANALYSTModerna upgraded by Wolfe ResearchWolfe Research upgraded Moderna from Underperform to Peer Perform
- ANALYSTModerna upgraded by BofA SecuritiesBofA Securities upgraded Moderna from Underperform to Neutral
- ANALYSTModerna upgraded by William BlairWilliam Blair upgraded Moderna from Mkt Perform to Outperform
- PRMerck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV MelanomaFirst and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran autogene in combination with KEYTRUDA Intismeran autogene is an mRNA-based individualized neoantigen therapy (INT) designed specifically for each patient based on the unique set of mutations within their tumor to train and activate the immune system to recognize and fight cancer Merck (NYSE:MRK), known as MSD outside of the United S
- SECSEC Form SCHEDULE 13G filed by Moderna Inc.SCHEDULE 13G - Moderna, Inc. (0001682852) (Subject)
- INSIDERChief Executive Officer Bancel Stephane exercised 751,715 shares at a strike of $19.15 and sold $28,715,011 worth of shares (499,246 units at $57.52) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 6,440,260 units (SEC Form 4) to satisfy withholding tax4 - Moderna, Inc. (0001682852) (Issuer)
MRNA FAQ
7 questionsWhat does Moderna Inc. do?
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with...Where does MRNA stock trade?
Moderna Inc. (MRNA) is listed on NASDAQ.What sector and industry is MRNA in?
Moderna Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Moderna Inc. go public?
Moderna Inc. (MRNA) completed its IPO in 2018.What are analysts saying about MRNA?
Moderna Inc. has had 8 recent analyst actions on file. The most recent action was from Rothschild & Co Redburn: Sell on 2026-09-03. Recent price targets range from $2500.00 to $3400.00.What companies are similar to MRNA?
Notable peers in the same industry include MRK (Merck & Company Inc.), AZN (AstraZeneca PLC), PFE (Pfizer Inc.), GSK (GSK plc), BNTX (BioNTech SE). Compare MRNA side-by-side with any of them on Quantisnow.How can I track MRNA on Quantisnow?
Quantisnow aggregates Moderna Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRNA to receive live email and push alerts on every new disclosure.